Boston Scientific pursued Watchman sales beyond limited FDA approval, investigation says

Boston Scientific committed hundreds of millions of dollars to acquire the Watchman more than a decade ago, then faced a years-long debate at the Food and Drug Administration over whether to approve it. The FDA ultimately cleared the device for a limited pool of patients, but the company was prepared with a plan for something much larger, according to the investigation. More than 800,000 Watchman devices have now been implanted around the world.

The evidence in the story centers on Boston Scientific's acquisition and regulatory history, not on a new clinical trial. The investigation says Boston Scientific endured a protracted FDA review before receiving approval for a restricted group, then moved to expand uptake of the implant. It also notes the device's global reach, citing more than 800,000 implants. The article itself is behind a paywall, so the full documentation behind the claims is not available in the excerpt.

This pattern is familiar in medical devices: a company can invest heavily in a product, win a narrow approval, then rely on sales force momentum, physician education, and reimbursement pathways to broaden use. The Watchman case highlights how commercial incentives can shape the pace of adoption, especially when long-term safety and comparative effectiveness data evolve after launch. Regulators often approve devices based on premarket trials, while postmarket studies and real-world registries can refine risk-benefit understanding over time.

The stakes fall on patients, physicians, and health systems. If a device is used far beyond the population studied in pivotal trials, clinicians may face uncertain benefit for some patients and hospitals may absorb costs or complications. For Boston Scientific, the investigation raises questions about whether sales strategy kept pace with the evidence. For regulators and payers, it underscores the need to match reimbursement and clinical guidance to the populations where benefit is best established.